Brightgene Bio-medical Technology Co Ltd
688166
Company Profile
Business description
Brightgene Bio-medical Technology Co Ltd is a pharmaceutical company engaged in research, development and production of new drugs and high-end generic drugs. The company develops macrolides, peptides, polysaccharides, heterocycles, azoles, azines, phenyl ethers, tetracyclines, and production of non-pharmaceutical macrolides, peptides, polysaccharides, heterocycles, azoles, azines, benzene Ethers, tetracyclines.
Contact
Xinghu Street, Industrial Park
Building C25-C28, Bio-Nano Park, No. 218
Suzhou215123
CHNT: +86 51262620988
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,151
Stocks News & Analysis
stocks
Wildly overvalued ASX stock is skating on thin ice
This company dominates its industry and could be flirting with regulatory intervention.
stocks
Uber flexes its network effect and delivers strong result
Uber’s business is humming along but autonomous vehicles add uncertainty to the longer term outlook.
stocks
Ask the analyst: Are Qantas shares a value trap?
Qantas’ pandemic woes seem a distant memory. But could the party end sooner than investors think?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,102.00 | 9.10 | -0.10% |
| CAC 40 | 7,709.32 | 74.29 | 0.97% |
| DAX 40 | 24,192.50 | 268.14 | 1.12% |
| Dow JONES (US) | 43,848.49 | 344.63 | -0.78% |
| FTSE 100 | 9,100.77 | 63.54 | -0.69% |
| HKSE | 25,081.63 | 171.00 | 0.69% |
| NASDAQ | 21,109.89 | 59.53 | -0.28% |
| Nikkei 225 | 41,059.15 | 264.29 | 0.65% |
| NZX 50 Index | 12,887.10 | 6.94 | 0.05% |
| S&P 500 | 6,314.72 | 30.34 | -0.48% |
| S&P/ASX 200 | 8,831.40 | 12.30 | -0.14% |
| SSE Composite Index | 3,639.67 | 5.67 | 0.16% |